Lena Åredal Appointed New CEO of SyntheticMR AB (publ)
13 juni, 08:56
Lena Åredal Appointed New CEO of SyntheticMR AB (publ)
June 13, 2025
The Board of Directors of SyntheticMR AB (publ) has appointed Lena Åredal as the company’s new Chief Executive Officer. She will assume the position no later than December 15, 2025. Until then, Acting CEO Johanna Norén will continue in her interim role and thereafter return to her position as CFO.
Lena Åredal currently serves as CEO of Perimed, a Swedish medtech company specializing in microcirculation diagnostics with global sales. During her tenure at Perimed, she has been responsible for the company’s OEM partnerships, established a direct sales organization in the United States, restructured its global distribution network, and led the company’s first external capital raise. Previously, Lena held several senior commercial positions at Baxter in the Nordic region, where she built sales organizations and played a key role in multiple acquisition and integration processes. She holds a Master’s degree in Public Health from Karolinska Institutet and has spent her entire career in the Life Science sector.
“In Lena, we have found the leader we have been looking for to guide SyntheticMR through its next phase of development. Her proven commercial drive and ability to build high-performing teams are key strengths as we aim to accelerate the company’s growth. We are entering a phase where, for example, the monitoring of rare but serious adverse drug reactions will drive increased demand for MRI examinations – an area where our technology is uniquely positioned to add value. The Board looks forward to welcoming Lena to the company as soon as possible,” says Gisli Hennermark, Chairman of the Board of SyntheticMR.
For further information, please contact:
Gisli Hennermark, Chairman of the Board, +46 70-420 83 00
Johanna Norén, Acting CEO, +46 70-619 21 00
This disclosure contains information that SyntheticMR AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 13-06-2025 08:56 CET.
SyntheticMR AB (publ) develops innovative imaging solutions that enhance MRI workflow efficiency and diagnostic precision. SyntheticMR’s SyMRI Neuro solution measures brain absolute tissue properties and generates multiple contrast-weighted images, performs automatic segmentation of biomarkers, and delivers quantitative data in a single fast scan. Combinostics, a SyntheticMR company, offers the AI-powered cNeuro suite of products that help clinicians make a difference in the lives of patients with neurological disorders.
SyntheticMR is headquartered in Linköping, Sweden, with an additional office in Tampere, Finland. For more information, please visit syntheticmr.com and combinostics.com
Ämnen i artikeln
Lena Åredal Appointed New CEO of SyntheticMR AB (publ)
13 juni, 08:56
Lena Åredal Appointed New CEO of SyntheticMR AB (publ)
June 13, 2025
The Board of Directors of SyntheticMR AB (publ) has appointed Lena Åredal as the company’s new Chief Executive Officer. She will assume the position no later than December 15, 2025. Until then, Acting CEO Johanna Norén will continue in her interim role and thereafter return to her position as CFO.
Lena Åredal currently serves as CEO of Perimed, a Swedish medtech company specializing in microcirculation diagnostics with global sales. During her tenure at Perimed, she has been responsible for the company’s OEM partnerships, established a direct sales organization in the United States, restructured its global distribution network, and led the company’s first external capital raise. Previously, Lena held several senior commercial positions at Baxter in the Nordic region, where she built sales organizations and played a key role in multiple acquisition and integration processes. She holds a Master’s degree in Public Health from Karolinska Institutet and has spent her entire career in the Life Science sector.
“In Lena, we have found the leader we have been looking for to guide SyntheticMR through its next phase of development. Her proven commercial drive and ability to build high-performing teams are key strengths as we aim to accelerate the company’s growth. We are entering a phase where, for example, the monitoring of rare but serious adverse drug reactions will drive increased demand for MRI examinations – an area where our technology is uniquely positioned to add value. The Board looks forward to welcoming Lena to the company as soon as possible,” says Gisli Hennermark, Chairman of the Board of SyntheticMR.
For further information, please contact:
Gisli Hennermark, Chairman of the Board, +46 70-420 83 00
Johanna Norén, Acting CEO, +46 70-619 21 00
This disclosure contains information that SyntheticMR AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 13-06-2025 08:56 CET.
SyntheticMR AB (publ) develops innovative imaging solutions that enhance MRI workflow efficiency and diagnostic precision. SyntheticMR’s SyMRI Neuro solution measures brain absolute tissue properties and generates multiple contrast-weighted images, performs automatic segmentation of biomarkers, and delivers quantitative data in a single fast scan. Combinostics, a SyntheticMR company, offers the AI-powered cNeuro suite of products that help clinicians make a difference in the lives of patients with neurological disorders.
SyntheticMR is headquartered in Linköping, Sweden, with an additional office in Tampere, Finland. For more information, please visit syntheticmr.com and combinostics.com
Ämnen i artikeln
-992x558.jpg&w=3840&q=75)
Veckans analyser
.jpg&w=3840&q=75)
-992x558.png&w=3840&q=75)
-992x558.jpg&w=3840&q=75)
Fortnox-budet
-992x558.png&w=3840&q=75)
Veckans analyser
Fortnox-budet
Marknadsöversikt
1 DAG %
Senast
1 mån
Privatekonomi med Placeras expert
Affärsvärlden
-160x160.png&w=3840&q=75)
